EUVIMEDEUVIMED entdecken
MetaanalyseÜbersichtsarbeitOpen Access · CC BY 4.0

Navigating the Sotatercept landscape: A meta‐analysis of clinical outcomes

Amir Nasrollahizadeh, Hamidreza Soleimani, Ali Nasrollahizadeh, Seyedeh Melika Hashemi, Kaveh Hosseini

Clinical Cardiology · 2024

DOI: 10.1002/clc.24173 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical Cardiology, 2024. Verfasst von Amir Nasrollahizadeh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Anemia, Pulmonary Arterial Hypertension, Recombinant Fusion Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary arterial hypertension (PAH) is a widespread condition that affects around 1% of the global population, with a higher prevalence among older individuals. The approach to managing PAH has undergone significant changes, requiring extensive treatment strategies. Sotatercept, an FDA‐approved medication, has recently attracted attention for its potential role in PAH therapy. However, information on its safety and effectiveness is scarce. In this study, we performed a meta‐analysis of existing randomized clinical trials to assess the impact of Sotatercept on PAH patients. Our findings revealed that those treated with Sotatercept showed greater improvement in pulmonary vascular resistance and World Health Organization functional class compared with placebo recipients. The occurrence of adverse events was similar between both groups. Importantly, the Sotatercept group displayed a considerably higher number of cases with an increase in hemoglobin levels. Considering that about 33% of PAH patients experience anemia and both anemia and polycythemia can adversely affect disease prognosis, additional research is necessary to establish the potential advantages and disadvantages of Sotatercept as a treatment choice, specifically regarding its erythropoietic properties.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnemiaPulmonary Arterial HypertensionRecombinant Fusion ProteinsHumansPrognosisRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

SotaterceptWHO functional classhemoglobinpulmonary hypertensionvascular resistance

Substanzen

Recombinant Fusion Proteinssotatercept

Autor:innen und Institutionen

  • Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Zitieren

APA

Nasrollahizadeh, A., Soleimani, H., Nasrollahizadeh, A., Hashemi, S. M., & Hosseini, K. (2024). Navigating the Sotatercept landscape: A meta‐analysis of clinical outcomes. Clinical Cardiology. https://doi.org/10.1002/clc.24173

Vancouver

Nasrollahizadeh A, Soleimani H, Nasrollahizadeh A, Hashemi SM, Hosseini K. Navigating the Sotatercept landscape: A meta‐analysis of clinical outcomes. Clinical Cardiology. 2024. doi:10.1002/clc.24173

BibTeX
@article{Nasrollahizadeh2024,
  author = {Nasrollahizadeh, Amir and Soleimani, Hamidreza and Nasrollahizadeh, Ali and Hashemi, Seyedeh Melika and Hosseini, Kaveh},
  title = {Navigating the Sotatercept landscape: A meta‐analysis of clinical outcomes},
  journal = {Clinical Cardiology},
  year = {2024},
  doi = {10.1002/clc.24173}
}
Kostenlos starten →